Suppr超能文献

组蛋白去乙酰化酶和 DNA 甲基转移酶抑制剂对雄激素非依赖性前列腺癌细胞系雄激素受体基因表达的影响。

Effect of histone deacetylase and DNA methyltransferase inhibitors on the expression of the androgen receptor gene in androgen-independent prostate cancer cell lines.

机构信息

Laboratory of Molecular Pathology, Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 775 15 Olomouc, Czech Republic.

出版信息

Oncol Rep. 2013 May;29(5):2039-45. doi: 10.3892/or.2013.2344. Epub 2013 Mar 13.

Abstract

Androgen receptor (AR) expression in prostate cancer (CaP) cells varies due to the multiple changes including epigenetic modifications such as DNA methylation and histone deacetylation. DNA methyltransferase and histone deacetylase inhibitors are promising for the treatment of CaP. The aim of our study was to analyze the 5-aza-2'-deoxycytidine (Aza‑dC) and sodium butyrate (NaB) effects on CaP cells with modified AR gene expression. The androgen-independent human prostate cancer cell lines PC3 (lacking a functional AR) and DU145 (strongly limited expression due to methylations in the AR gene) were used. PCR of bisulfite-modified DNA and RT-PCR with bisulfite-sequencing were used for AR gene analysis of DU145 and PC3 cells following their treatment with Aza-dC and/or NaB. Re-acetylated histones around the AR gene were detected by conventional PCR of immunoprecipitated DNA obtained from treated cells. In both cell lines without the AR expression, the combined treatment was followed with significant decrease of cell viability. The co-treatment of DU145 cells caused site-specific demethylation in the AR promoter region followed by gene re-expression and increased acetylation in histones H3 and H4. The co-treatment with Aza-dC and NaB was the most effective in demethylation and re-expression of the AR gene. In the AR gene promoter, the location and density of deme-thylated CpGs indicated the existence of distinct promoter hot spot that could be a target of AR gene inactivation therapy of CaP patients during androgen deprivation.

摘要

雄激素受体 (AR) 在前列腺癌 (CaP) 细胞中的表达因多种变化而不同,包括表观遗传修饰,如 DNA 甲基化和组蛋白去乙酰化。DNA 甲基转移酶和组蛋白去乙酰化酶抑制剂是治疗 CaP 的有前途的药物。我们的研究目的是分析 5-氮杂-2'-脱氧胞苷 (Aza-dC) 和丁酸钠 (NaB) 对 AR 基因表达改变的 CaP 细胞的影响。使用雄激素非依赖性人前列腺癌细胞系 PC3(缺乏功能性 AR)和 DU145(由于 AR 基因中的甲基化而表达受限)。用亚硫酸氢盐修饰的 DNA 的 PCR 和亚硫酸氢盐测序的 RT-PCR 用于 AR 基因分析 DU145 和 PC3 细胞在 Aza-dC 和/或 NaB 处理后。用常规 PCR 检测从处理过的细胞中获得的免疫沉淀 DNA 周围重新乙酰化的组蛋白。在没有 AR 表达的两种细胞系中,联合治疗后细胞活力显著下降。对 DU145 细胞的联合治疗导致 AR 启动子区域的特异性去甲基化,随后基因重新表达,并增加组蛋白 H3 和 H4 的乙酰化。Aza-dC 和 NaB 的联合治疗在 AR 基因的去甲基化和重新表达方面最有效。在 AR 基因启动子中,去甲基化 CpG 的位置和密度表明存在独特的启动子热点,这可能是雄激素剥夺期间 CaP 患者 AR 基因失活治疗的靶点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验